Teachers Advisors LLC Has $16.96 Million Stake in Sangamo Therapeutics Inc (SGMO)
Teachers Advisors LLC grew its stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 7.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,000,485 shares of the biopharmaceutical company’s stock after purchasing an additional 73,264 shares during the period. Teachers Advisors LLC owned approximately 0.98% of Sangamo Therapeutics worth $16,958,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its position in shares of Sangamo Therapeutics by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 105,711 shares of the biopharmaceutical company’s stock worth $1,792,000 after buying an additional 7,817 shares during the period. MetLife Investment Advisors LLC boosted its position in shares of Sangamo Therapeutics by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 73,166 shares of the biopharmaceutical company’s stock worth $1,240,000 after buying an additional 26,009 shares during the period. United Services Automobile Association boosted its position in shares of Sangamo Therapeutics by 9.2% during the second quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock worth $818,000 after buying an additional 4,860 shares during the period. BlackRock Inc. boosted its position in shares of Sangamo Therapeutics by 3.0% during the third quarter. BlackRock Inc. now owns 8,322,311 shares of the biopharmaceutical company’s stock worth $141,063,000 after buying an additional 239,190 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in shares of Sangamo Therapeutics by 194.9% during the third quarter. Russell Investments Group Ltd. now owns 105,894 shares of the biopharmaceutical company’s stock worth $1,795,000 after buying an additional 69,984 shares during the period. Institutional investors and hedge funds own 62.27% of the company’s stock.
SGMO has been the subject of several research analyst reports. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, November 6th. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 10th. Wedbush set a $11.00 price objective on Sangamo Therapeutics and gave the company a “hold” rating in a research note on Monday, November 19th. JPMorgan Chase & Co. cut Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $11.00 in a research note on Wednesday, November 14th. Finally, Guggenheim cut Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 price objective on the stock. in a research note on Friday, November 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $18.83.
Sangamo Therapeutics stock traded up $0.45 during midday trading on Monday, reaching $8.17. The company’s stock had a trading volume of 753,773 shares, compared to its average volume of 2,242,694. Sangamo Therapeutics Inc has a fifty-two week low of $6.26 and a fifty-two week high of $27.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.32 and a quick ratio of 6.32. The stock has a market cap of $788.16 million, a PE ratio of -11.67 and a beta of 2.84.
Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. Sangamo Therapeutics had a negative return on equity of 22.06% and a negative net margin of 88.78%. The company had revenue of $23.56 million for the quarter, compared to analysts’ expectations of $26.96 million. During the same period last year, the firm earned ($0.15) earnings per share. Sangamo Therapeutics’s quarterly revenue was up 99.5% on a year-over-year basis. On average, research analysts expect that Sangamo Therapeutics Inc will post -0.72 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/teachers-advisors-llc-has-16-96-million-stake-in-sangamo-therapeutics-inc-sgmo/2813217.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Further Reading: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.